Theranexus (EPA:ALTHX) | WebDisclosure

Basculer en Français

10355	Companies
215502	Keywords
145322	Articles
114166	Press releases

Home
Companies
Theranexus

PRESS RELEASE

published on 07/11/2024 at 18:45, 1 year 9 months ago

Theranexus publishes its cash position as of 30 June 2024 and presents an update on the progress of Batten-1
Biopharmaceutical company Theranexus announces implementation of new equity line to finance Phase III trial for Batten-1 drug in juvenile Batten disease. Update on Batten-1 program included

Biopharmaceutical Company Phase III Trial Theranexus Batten-1 Equity Line
BRIEF

published on 07/03/2024 at 07:35, 1 year 10 months ago

Theranexus, CRNL et CERMEP lauréats du projet "Pacte de recherche 2024" d'Auvergne-Rhône-Alpes

Recherche Auvergne-Rhône-Alpes Theranexus Neurologie Neuroimagerie
BRIEF

published on 07/03/2024 at 07:35, 1 year 10 months ago

Theranexus, CRNL and CERMEP winners of the Auvergne-Rhône-Alpes “Research Pact 2024” project

Research Neurology Auvergne-Rhône-Alpes Theranexus Neuroimaging
PRESS RELEASE

published on 07/03/2024 at 07:30, 1 year 10 months ago

THERANEXUS, LE CENTRE DE RECHERCHE EN NEUROSCIENCES DE LYON ET LE CERMEP, LAURÉATS DU PROJET " PACTE DE RECHERCHE 2024 " DE LA REGION AUVERGNE-RHÔNE-ALPES
Theranexus, CRNL, and CERMEP win 'Pacte de recherche 2024' project in Auvergne-Rhône-Alpes to develop new neuroimaging tools for rare neurological diseases treatment

Theranexus Rare Neurological Diseases Neuroimaging CRNL CERMEP
PRESS RELEASE

published on 07/03/2024 at 07:30, 1 year 10 months ago

THERANEXUS, LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP WIN THE "2024 RESEARCH PACT" PROJECT FOR THE AUVERGNE-RHÔNE-ALPES REGION
Theranexus, Lyon Neuroscience Research Center, and CERMEP win research pact project 'IMASO' in Auvergne-Rhône-Alpes Region for preclinical neuroimaging in rare neurological diseases

Theranexus Neurological Diseases Research Pact Auvergne-Rhône-Alpes Region Preclinical Neuroimaging
BRIEF

published on 06/06/2024 at 07:35, 1 year 11 months ago

Theranexus et BBDF annoncent des résultats positifs à 18 mois pour Batten-1 dans une étude de phase 1/2

Theranexus Batten-1 Maladie De Batten BBDF Neurofilaments
BRIEF

published on 06/06/2024 at 07:35, 1 year 11 months ago

Theranexus and BBDF Announce Positive Results at 18 Months for Batten-1 in Phase 1/2 Study

Theranexus Batten-1 BBDF Batten Disease Neurofilaments
PRESS RELEASE

published on 06/06/2024 at 07:30, 1 year 11 months ago

Theranexus et BBDF confirment les résultats positifs à 18 mois de Batten-1 dans l'étude de phase 1/2 sur les neurofilaments, un biomarqueur de la mort neuronale
Theranexus et BBDF confirment les résultats positifs à 18 mois de l'étude de phase 1/2 sur les neurofilaments, biomarqueur de la mort neuronale, concernant le médicament Batten-1 dans la maladie de Batten (CLN3)

Theranexus Batten-1 Maladie De Batten BBDF Neurofilaments
PRESS RELEASE

published on 06/06/2024 at 07:30, 1 year 11 months ago

Theranexus and BBDF confirm positive 18-month results for Batten-1 in Phase I/II trial based on neurofilaments, a biomarker of neuronal death
Theranexus and BBDF confirm positive results in Phase I/II trial evaluating Batten-1 drug for CLN3 Batten disease after 18 months of treatment, showing decline in NfL biomarker levels and therapeutic potential

Theranexus Batten-1 BBDF CLN3 Batten Disease Neurofilament Light Chains
BRIEF

published on 05/02/2024 at 07:35, 2 years ago

Theranexus dévoile son document d'enregistrement universel pour 2023

2023 Biopharmaceutique Document D'Enregistrement Universel Theranexus Maladies Neurologiques Rares

Accesswire

Published on 05/07/2026 at 02:00, 3 minutes ago

Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York
Published on 05/06/2026 at 23:30, 2 hours 33 minutes ago

Stabilis Solutions Announces First Quarter 2026 Results
Published on 05/06/2026 at 23:05, 2 hours 58 minutes ago

Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity
Published on 05/06/2026 at 23:00, 3 hours 3 minutes ago

Green Bridge Metals Strengthens Technical and Strategic Team as 2026 Work Programs Advance
Published on 05/06/2026 at 22:10, 3 hours 53 minutes ago

Banyan Gold Announces Closing of $46.5 Million Private Placement

View all ACCESSWIRE

EQS Group

Published on 05/07/2026 at 00:47, 1 hour 16 minutes ago

Blue Cap AG expands portfolio through the acquisition of Janoschka AG
Published on 05/07/2026 at 00:43, 1 hour 19 minutes ago

EQS-Adhoc: Blue Cap AG Acquires Janoschka AG and Adjusts Forecast Due to Transaction
Published on 05/06/2026 at 20:32, 5 hours 31 minutes ago

EQS-Adhoc: Kontron AG: ADHOC Kontron AG / Potential Public Takeover Bid by Ennoconn Corporation
Published on 05/06/2026 at 20:22, 5 hours 41 minutes ago

EQS-Adhoc: ams-OSRAM AG: ams OSRAM delivers strong Q1 results, enters AI market through a development agreement with a leading AI photonics customer and sees path to positive Free Cash Flow in 2027
Published on 05/06/2026 at 19:18, 6 hours 45 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 05/06/2026 at 18:00, 8 hours 3 minutes ago

Mise à disposition des documents relatifs à l'AG du 4 juin 2026
Published on 05/06/2026 at 18:00, 8 hours 3 minutes ago

Access to information in respect of the General Shareholders’ Meeting to be held on June 4, 2026
Published on 05/06/2026 at 18:00, 8 hours 3 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of April 30, 2026
Published on 05/06/2026 at 18:00, 8 hours 3 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 30 avril 2026
Published on 05/06/2026 at 17:45, 8 hours 18 minutes ago

Information concerning the total number of voting rights and shares 2026 04 30

View all LES ECHOS COMFI WIRE